Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2012 Dec;13(18):2673-85. doi: 10.1517/14656566.2012.742064. Epub 2012 Nov 10.

Atorvastatin calcium plus amlodipine for the treatment of hypertension.

Author information

1
University Hospital Ramón y Cajal, Carretera de Colmenar Km 9.100, Madrid 28034, Spain.

Abstract

INTRODUCTION:

Hypertension (HTN) and dyslipemia (DYL) are two of the major modifiable cardiovascular (CV) risk factors, determinants in the development of cerebrovascular and coronary heart disease (CHD). Many patients have both risk factors which increase their total CV risk compared with patients with only one risk factor. Treatment guideline recommendations are poorly implemented in real practice, in part due to numerous and complicated drug regimes which hamper patient´s adherence.

AREAS COVERED:

In this article the authors describe the first combined fixed-dose pill of an antihypertensive and a lipid-lowering agent, the single-pill combination of amlodipine besylate and atorvastatin calcium (SPAA). They summarize the pharmacokinetic and pharmacodynamic properties of both compounds and the main randomized clinical studies, as well as real-world observational studies, made with the new combined formulation.

EXPERT OPINION:

The use of the single-pill amlodipine and atorvastatin is an adequate option for the clinician to treat hypertensive patients with DYL or high CV risk burden, with proven efficacy, tolerability, cost-effectiveness, and the advantage of improving patient treatment compliance.

PMID:
23140185
DOI:
10.1517/14656566.2012.742064
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center